Background {#Sec1}
==========

Psoriasis is a multisystem inflammatory disease that is underdiagnosed and undertreated despite its prevalence and considerable effect on quality of life (QoL). Beyond skin and joint involvement, psoriasis is also associated with various important medical and psychiatric conditions that require timely therapy to improve long-term outcomes \[[@CR1]\]. Psoriasis is one of the most common chronic skin diseases, affecting a large proportion of the population \[[@CR2]\]. Korea National Health Insurance data showed that the number of patients with psoriasis in Korea was 168,862 in 2013 and had increased by 1.5% per year for 5 years from 2011 to 2016. Consequently, the economic burden of disease for psoriasis has also increased from 11 million USD to 21 million USD during this period \[[@CR3]\]. Despite this increase in the number of patients and burden of disease for psoriasis, the misconception that skin diseases are less serious relative to other illnesses remains.

Skin diseases, including psoriasis, have been shown to exert a significant adverse effect on patients' health-related quality of life (HRQoL). Psoriasis can influence various aspects of patients' lives including their careers, incomes, relationships, and physical intimacy \[[@CR4], [@CR5]\]. It can increase in severity, and moderate-to-severe psoriasis could compromise patients' QoL considerably \[[@CR6]\].

Psoriasis could lead to different types of stressful experience for patients \[[@CR7]\]. Literature reviews have documented various difficulties in coping with the chronic disease, including those concerning treatment management, symptom control, management of assaults on body image and self-esteem, and the potential to lead a normal life \[[@CR8]\]. Individuals differ in their adjustment to a chronic illness. Patients with psoriasis report that the condition has various psychosocial consequences, such as social isolation and feelings of anger, depression, shame, and anxiety \[[@CR9]\].

Improvement in QoL is an important treatment goal for patients with psoriasis \[[@CR10]\]. HRQoL measures are particularly important for dermatological conditions, as although not usually life-threatening, they frequently exert a strong influence on patients' psychosocial status, social relationships, and everyday activities. The Body Surface Area (BSA) tool is used to measure patients' health status; however, objective clinical severity is not always linearly associated with patients' subjective distress, as one might expect \[[@CR11]\].

Therefore, this national study aimed to identify the socioeconomic and clinical characteristics affecting HRQoL in patients with psoriasis, using Internet-based questionnaires.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

We conducted a cross-sectional study between March and June 2015, using data obtained via an Internet-based survey in Korea. Participants' socioeconomic and clinical characteristics and HRQoL were examined simultaneously using a structured questionnaire.

Study participants and data collection {#Sec4}
--------------------------------------

The participants were recruited via e-mail and invited to participate in the survey in cooperation with the Korea Psoriasis Association, a nationwide patient association with 17,092 members as of 2015. An invitation letter was sent to 1685 members who had registered for the Association at least once in the past three years as a regular member and were aged 19 years or older (at time of registration). Those invited were informed that they could withdraw their consent at any time during the study without incurring any negative consequences and that their data would be excluded from the study. This study included a total of 299 patients (response rate was 17.7%) who (a) were diagnosed with psoriasis at a clinic or a hospital, (b) signed an informed consent form, and (c) answered all questions. The study protocol was reviewed and approved by the Institutional Review Board at Chung-Ang University (IRB Number: 1041078--201,501-HRSB-007-01).

Measurement {#Sec5}
-----------

The independent variables included demographic, socioeconomic, and clinical characteristics. Demographic and socioeconomic characteristics included gender, age, marital status, educational level, employment status, annual income, occupation, difficulty securing employment because of psoriasis, and psoriasis-related resignation from work.

Clinical characteristics were examined in terms of duration, severity, affected area of the body, and treatment. Psoriasis severity was assessed according to the BSA affected by psoriasis, using the question "How many times the size of your palm is the entire area in which you have psoriasis?" This measurement was based on the assumption that one's own palm area represents 1% of one's BSA \[[@CR12]\]. Those with affected BSAs of 10% or larger, 5% to 9%, and 5% or less were classified as patients with severe, moderate, and mild psoriasis, respectively \[[@CR12], [@CR13]\].

The Dermatology Life Quality Index (DLQI) was used to evaluate patients' psoriasis-related HRQoL impairment. The DLQI is a dermatology-specific QoL measuring instrument consisting of 10 questions asking patients to indicate how their skin disease has affected their HRQoL during the preceding week. The sum of the item scores provides a total score between 0 (no impact on HRQoL) and 30 (maximum impact on HRQoL) \[[@CR14]--[@CR16]\]. Scores of 11 or higher indicate severe HRQoL impairment. This survey employed a Korean version of DLQI which was validated by the Korean research team and added as a reference to the study \[[@CR17]\].

Statistical analysis {#Sec6}
--------------------

Participants' characteristics are presented as frequencies and proportions for categorical variables and means and standard deviations for continuous variables. Differences were evaluated using chi-squared tests and t tests, as appropriate.

Patients' DLQI scores were classified into the following five groups: Group 1: participants who reported no effects (scores 0--1), Group 2: participants who reported mild effects (scores 2--5), Group 3: participants who reported moderate effects (scores 6--10), Group 4: participants who reported severe effects (score 11--20), and Group 5: participants who reported very severe effects (scores 21--30), and frequencies and proportions were calculated for each group \[[@CR18]\].

Analyses of variance or t tests were performed to compare mean DLQI scores, and a chi-squared test was performed to assess the association of demographic, socioeconomic, and clinical factors with HRQoL in patients with scores of 11 or higher. Factors influencing impairment were identified using multivariate logistic regression analysis with backward elimination of factors with clinical/socioeconomic significance that included gender, age group (\< 40 years, ≥40 years), psoriasis severity (BSA \< 10%, BSA ≥ 10%), annual income (\< 48,000 USD, ≥ 48,000 USD), resignation from work because of psoriasis, psoriasis on the neck, use of oral medication for psoriasis, and use of herbal medication for psoriasis.

Results {#Sec7}
=======

Among 1685 patients invited via e-mail, 299 patients voluntarily participated in this survey (response rate, 17.7%). Table [1](#Tab1){ref-type="table"} shows participants' characteristics according to gender. Of the 299 participants, 224 (74.9%) were men, who were more likely to be older, married, in full-time employment, and earning higher incomes, relative to women. In addition, women tended to be more likely to have psoriasis on the neck and less likely to receive topical treatment relative to men.Table 1Characteristics of study participants with psoriasis by genderVariablesTotal (*n* = 299)Male (*n* = 224)Female (*n* = 75)N(%)N(%)N(%)*P*-valueGender Male224(74.9) Female75(25.1)Age (years) Mean, SD43.8±9.945.3±9.739.2±9.4\< 0.001 20--3995(31.8)57(25.4)38(50.7)\< 0.001 40--59181(60.5)146(65.2)35(46.7) 60--7923(7.7)21(9.4)2(2.7)Marital status Single75(25.1)48(21.4)27(36.0)0.038 Married196(65.6)155(69.2)41(54.7) Divorced/widowed26(8.7)21(9.4)7(9.3)Education level  ≤ High school65(21.7)43(19.2)22(29.3)0.143 College183(61.2)145(64.7)40(53.3) Graduate school49(16.4)36(16.1)13(17.3)Employment status Full-time213(71.2)171(76.3)42(56.0)0.003 Part-time27(9.0)18(8.0)9(12.0) Unemployed/student/housewife59(19.7)35(15.6)24(32.0)Annual income (USD)  \< 24,00033(11.0)20(8.9)13(17.3)0.003 24,000-47,99999(33.1)71(31.7)34(45.3) 48,000-71,99992(30.8)72(32.1)20(26.7)  ≥ 72,00069(23.1)61(27.2)8(10.7)Duration of psoriasis (years) Mean, SD21.3±1021.6±9.720.5±10.80.426 1--933(11.0)21(9.4)12(16.0)0.429 10--19113(37.8)88(39.3)25(33.3) 20--2989(29.8)67(29.9)22(29.3)  ≥ 3064(21.4)48(21.4)16(21.3)Severity of psoriasis (BSA) Mild (\< 5%)146(48.8)106(47.3)40(53.3)0.665 Moderate (5--9%)65(21.7)50(22.3)15(20.0) Severe (≥10%)88(29.4)68(30.4)20(26.7)Site of psoriasis Head233(77.9)179(79.9)54(72.0)0.153 Face141(47.2)107(47.8)34(45.3)0.715 Neck82(27.4)51(22.8)31(41.3)0.002 Shoulder115(38.5)89(39.7)26(34.7)0.435 Chest/abdomen191(63.9)141(62.9)50(66.7)0.562 Back/buttocks232(77.6)174(77.7)58(77.3)0.951 Arm229(76.6)169(75.4)60(80.0)0.420 Hand141(47.2)111(49.6)30(40.0)0.151 Leg263(88.0)201(89.7)62(82.7)0.104 Foot128(42.8)95(42.4)33(44.0)0.810Treatment for psoriasis Topical treatment246(82.3)190(84.8)56(74.7)0.046 Prescribed oral medication135(45.2)97(43.3)38(50.7)0.267 Herbal medication88(29.4)62(27.7)26(34.7)0.250 Phototherapy142(47.5)110(49.1)32(42.7)0.334 Injections except biologics45(15.1)31(13.8)14(18.7)0.312 Biological therapy28(9.4)22(9.8)6(8.0)0.639*BSA* body surface area

Participants' mean DLQI score was 12.4 (SD = 7.6), and 53.8% (*n* = 161) exhibited severe HRQoL impairment (DLQI scores ≥11). Specifically, the proportions of participants in Groups 1 2, 3, 4, and 5 were 4.0%, 16.7%, 25.4%, 37.1%, and 16.7%, respectively (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Distribution of Dermatology Life Quality Index (DLQI) score (%)

Table [2](#Tab2){ref-type="table"} shows the participants' DLQI scores according to their demographic and socioeconomic characteristics. The factors associated with high DLQI scores included female gender and age younger than 40 years, divorce or widowhood, education to high school level or lower, part-time or temporary employment or unemployment, and low income. In addition, DLQI scores were highest in patients who reported that they always or often experienced difficulty securing employment and resigned from work because of psoriasis.Table 2DLQI Scores according to demographic and socioeconomic factors in patients with psoriasisVariablesNo. of patientsDLQI Scores*p*-valueDLQI ≤10DLQI ≥11*p*-valueMean ± SDN(%)N(%)Total participants29912.4 ± 7.6138(46.2)161(53.8)Gender Male22411.6 ± 7.50.003117(52.2)107(47.8)\< 0.001 Female7514.7 ± 7.721(28.0)54(72.0)Age (years) 20--399513.9 ± 8.20.03838(40.0)57(60.0)0.258 40--5918111.9 ± 7.287(48.1)94(51.9) 60--792310.3 ± 7.513(56.5)10(43.5)Marital status Single7514.7 ± 8.3\< 0.00129(38.7)46(61.3)0.009 Married19611.0 ± 6.9102(52.0)94(48.0) Divorced/widowed2815.9 ± 8.07(25.0)21(75.0)Education level  ≤ High school6514.8 ± 7.40.01021(32.3)44(67.7)0.029 College18311.5 ± 7.495(51.9)90(49.2) Graduate school4912.6 ± 8.022(44.9)27(55.1)Employment status Full-time21311.4 ± 7.20.002106(49.8)107(50.2)0.127 Part-time2715.8 ± 8.29(33.3)18(66.7) Unemployed/student/housewife5914.3 ± 8.123(39.0)36(61.0)Type of employment Employer or self-employed5911.2 ± 6.8\< 0.00131(52.5)28(47.5)0.098 Regular job15911.4 ± 7.278(49.1)81(50.9) Temporary job1718.2 ± 8.84(23.5)13(76.5) Unemployed6414.5 ± 8.025(39.1)39(60.9)Annual income (USD)  \< 24,0003318.3 ± 8.3\< 0.0017(21.2)26(78.8)\< 0.001 24,000-47,99910513.9 ± 7.238(36.2)67(63.8) 48,000-71,9999210.7 ± 7.349(53.3)43(46.7)  ≥ 72,000699.5 ± 6.244(63.8)25(36.2)Experience of difficulty in finding jobs due to psoriasis Always/often8717.9 ± 7.3\< 0.00115(17.2)72(82.8)\< 0.001 Somewhat/sometimes/never21210.1 ± 6.5123(58.0)89(42.0)Experience of quitting jobs due to psoriasis Yes9215.9 ± 8.0\< 0.00123(25.0)69(75.0)\< 0.001 No/Inapplicable20710.8 ± 6.9115(55.6)92(44.4)*DLQI* Dermatology life quality index

Patients with severe psoriasis (BSA ≥ 10%) exhibited high DLQI scores (15.0 ± 8.0), indicating severe HRQoL impairment (Table [3](#Tab3){ref-type="table"}). Further, DLQI scores in patients with psoriasis on the face, neck, shoulder, or foot were significantly higher relative to those observed in patients with psoriasis on other areas of the body (*p* \< .001). Patients who used oral or herbal medication exhibited greater HRQoL impairment relative to those who did not use these medications (*p* \< .05).Table 3DLQI Scores by clinical factors in patients with psoriasisVariablesNo. of patientsDLQI Scores*p*-valueDLQI ≤10DLQI ≥11*p*-valueMean ± SDN(%)N(%)Total participants29912.4 ± 7.6138(46.2)161(53.8)Duration of psoriasis (years) 1--93314.8 ± 8.30.20114(42.4)19(57.6)0.661 10--1911312.6 ± 7.850(44.2)63(55.8) 20--298911.5 ± 7.646(51.7)43(48.3)  ≥ 306412.0 ± 6.928(43.8)36(56.3)Severity of psoriasis (BSA) Mild (\< 5%)14610.5 ± 6.9\< 0.00180(54.8)66(45.2)0.005 Moderate (5--9%)6513.0 ± 7.629(44.6)36(55.4) Severe (≥10%)8815.0 ± 8.029(33.0)59(67.0)Site of psoriasis Head23313.0 ± 7.80.010101(43.3)132(56.7)0.067 Face14114.4 ± 8.2\< 0.00154(38.3)87(61.7)0.010 Neck8216.0 ± 7.5\< 0.00121(25.6)61(74.4)\< 0.001 Shoulder11515.2 ± 7.8\< 0.00141(35.7)74(64.3)0.004 Chest/abdomen19113.5 ± 7.60.00174(38.7)117(61.3)0.001 Back/buttocks23213.5 ± 7.7\< 0.00193(40.1)139(59.9)\< 0.001 Arm22913.2 ± 7.80.00197(42.4)132(57.6)0.017 Hand14114.2 ± 7.7\< 0.00151(36.2)90(63.8)0.001 Leg26312.4 ± 7.70.916120(45.6)143(54.4)0.622 Foot12814.7 ± 7.6\< 0.00143(33.6)85(66.4)\< 0.001Treatment for psoriasis Topical treatment24612.8 ± 7.60.048107(43.5)139(56.5)0.047 Prescribed oral medication13514.8 ± 7.9\< 0.00144(32.6)91(67.4)\< 0.001 Herbal medication8814.2 ± 7.80.00930(34.1)58(65.9)0.007 Phototherapy14213.8 ± 8.10.00257(40.1)85(59.9)0.047 Injections except biologics4515.1 ± 8.60.01116(35.6)29(64.4)0.122 Biological therapy2811.8 ± 8.90.63614(50.0)14(50.0)0.668*DLQI* Dermatology life quality index; BSA: body surface area

The proportion of HRQoL impairment level observed in women was twice that observed in men (odds ratio \[OR\] = 2.00, 95% confidence interval \[CI\]: 1.05--3.80). Patients with psoriasis on the neck exhibited significantly greater HRQoL impairment relative to those with psoriasis in other areas of the body (OR = 2.30, 95% CI: 1.20--4.43). Regarding socioeconomic status, patients who earned 40 million KRW (approximately 48,000 USD) or more showed lower levels of HRQoL impairment than those who had lower incomes (OR = 0.47, 95% CI: 0.28--0.80). Patients with severe HRQoL impairment used oral (OR = 2.04, 95% CI: 1.20--3.44) or herbal (OR = 1.86, 95% CI: 1.04--3.34) medications more frequently than those with less severe HRQoL impairment (Table [4](#Tab4){ref-type="table"}).Table 4Factors influencing HRQoL impairmentVariablesCrude odds ratio (95% CI)Adjusted odds ratio (95% CI)Female2.812(1.593--4.963)1.996(1.048--3.800)Age of 40 years or older0.693(0.423--1.136)1.311(0.719--2.389)BSA ≥ 10%2.174(1.292--3.657)1.383(0.739--2.589)Annual income ≥ USD 48,0000.354(0.220--0.568)0.471(0.276--0.804)Experience of quitting jobs due to psoriasis3.750(2.173--6.472)2.158(1.172--3.972)Psoriasis on neck3.399(1.935--5.969)2.304(1.199--4.428)Use of oral drugs for psoriasis2.777(1.728--4.464)2.036(1.204--3.443)Use of oriental medicines for psoriasis2.027(1.209--3.399)1.859(1.035--3.341)Dermatology life quality index cutoff score for severe quality of life impairment: ≥11, *HRQoL* health-related quality of life, *BSA* body surface area, *CI* confidence interval

Discussion {#Sec8}
==========

The results showed that HRQoL in patients with psoriasis was significantly associated with their demographic and socioeconomic characteristics and employment status. In addition, the presence of psoriasis on exposed areas was significantly associated with patients' HRQoL and employment status. Visibility is associated with self-esteem because appearance plays an important role in social and cultural settings \[[@CR19]\]. However, the overall Psoriasis Area Severity Index (PASI) score is weighted only by regional body surface area (BSA), failing to account for a disproportionate burden in more visible/sensitive locations \[[@CR7], [@CR8]\]. Given that the burden of psoriasis may be related to disease location and associated with QoL \[[@CR8]\], further research examining the impact of psoriasis on patient productivity is required.

Psoriasis has been associated with significant psychological distress, psychiatric morbidity, stigma, and reductions in HRQoL \[[@CR20]\]. In addition, the clinical severity of the condition, measured using the PASI, has been associated with patients' QoL \[[@CR21]\]. In the current study, the results showed that women were more likely to feel distressed or embarrassed about psoriasis relative to men. This finding is consistent with those of previous research conducted by Finlay et al., wherein men found it easier to cope with the social effects of psoriasis than women \[[@CR22], [@CR23]\]. Furthermore, stress research has provided an additional method for enhancing the understanding of differences between reactions of men and women's toward psoriasis and indicated that women are more susceptible to stress \[[@CR24], [@CR25]\]. Consequently, stress is more likely to exert a stronger impact on the psychological aspects of HRQoL in women than men \[[@CR26]\]. Therefore, the findings of this present study are congruent with those of previous studies. Moreover, some previous studies have shown that women were more likely to react to stress and the displayed greater discomfort and stigmatization than men \[[@CR25], [@CR27]\]. In addition, gender differences were observed in Short Form-12 mental component summary scores but not in general physical or skin-related HRQoL \[[@CR25]\].

With respect to financial status, a meaningful difference in HRQoL was observed between participants with annual incomes greater than 40 million KRW (48,000 USD) and those with annual incomes less than that. The Korean government established a maximum out-of-pocket payment limit to reduce patients' financial burden resulting from excessive medical expenses. This established limit is designed to cover excesses above the individual limit by income level and is implemented through the National Health Insurance Service. However, under the system, patients with low income cannot take advantage of their insurance benefit because they may have to pay a substantial out-of-pocket medical fee for psoriasis treatment and wait for 20 months for their refund. This may make it difficult to access more expensive and effective treatment options, such as biologics, which can lead to low QoL \[[@CR18]\].

Additionally, patients' job security is dependent on their disease severity, as it reduces their ability to work and may lead to early retirement \[[@CR28]\]. In a previous study, patients with moderate-to-severe psoriasis were estimated to experience a significant (15--20%) reduction in their ability to work following diagnosis \[[@CR29]\]. In another study, participants' productivity scores were negatively associated with disease severity, indicating greater impairment in patients with severe psoriasis, as they experienced symptoms of greater intensity and a larger reduction in HRQoL and productivity, relative to those experienced by patients with mild or moderate psoriasis \[[@CR30]\]. Therefore, physicians should be mindful of the impact of severe disease on patients' lives, including employment, and endeavor to address this issue.

In recent literature, attention has been focused on the role of psychological factors in the frequency of recurrence and remission, and treatment dynamics \[[@CR31]\] because the skin is important to aesthetics and appearance. It is also an important factor in nonverbal communication and interpersonal relationships, partly because it is involved in emotional expression. Therefore, chronic dermatological conditions exert a significant effect on patients' psychological health, self-esteem, and body image. Understandably, patients are very anxious about psoriasis on the neck, as it is difficult to conceal from others. Chronic stress and the related loss of positive self-image could also lead to social rejection, which is likely to exacerbate psoriatic symptoms \[[@CR32]\]. Consequently, stress could be considered a prognostic factor for psychosocial dysfunction in patients with psoriasis. Moreover, reduction of emotional well-being in proportion to the severity of skin changes could lead to reductions in subjective QoL and psychological functioning.

With respect to treatment, topical therapy, such as steroid cream or lotion, is frequently used to treat mild or moderate psoriasis. In addition, anthralin, tar, vitamin D derivatives (i.e., calcipotriol), and vitamin A (i.e., tazarotene) are popular oral medications, and systemic treatment for severe psoriasis includes methotrexate and cyclosporine as standard medication options in Korea. However, systemic treatments are likely to include side effects, such as clinically significant liver enzyme abnormalities, which could influence patients' QoL.

Psoriasis patients often enquire about the use of numerous herbal and oriental medicines; therefore, dermatologists should keep abreast of contemporary evidence regarding these agents. However, health professionals are cautious in their use of herbal medications, particularly those for psoriasis, because of availability and quality issues identified via research \[[@CR33]\].

This research was conducted with a limited number of patients who were registered in a patient group. In addition, the participants completed the questionnaires online; consequently, the study was restricted to patients who were available and able to use the Internet and a computer, which could have led to response bias and limited the generalizability of the findings to other patient groups. Furthermore, according to a previous study, in South Korea as of 2015, the male-to-female ratio of patients with psoriasis was 1.3:1, and the percentage of elderly patients over 60 years old with psoriasis was 25% \[[@CR34]\]. Compared with the entire psoriasis population, the present study included fewer women (25.1%) with a lower QoL, and the results may be underestimated. On the other hand, there is a possibility that the results are overestimated because of the inclusion of fewer elderly people (7.7%) with a higher QoL. In terms of research design, these findings could not explain the robust causal inference because this study was performed using a cross-sectional design and may only able to provide snapshots of psoriasis patients' current situations. In addition, further research is required to examine the impact of psoriasis on patient productivity.

Conclusion {#Sec9}
==========

Treatment goals and success should be based on patients' QoL in the provision of patient-centered care. However, treatment outcomes can be measured easily using objective criteria such as the Patient Benefit Index global score and the PASI. Therefore, patients' demographic and socioeconomic characteristics and employment status may be ignored, despite being significantly associated with psoriasis patients' HRQoL. Patients' employment status and the presence of psoriasis in exposed areas could be significantly associated with their QoL and satisfaction with treatment. Through this research, it was shown that HRQoL of psoriasis patients was a major factor in managing the disease. Therefore, when physicians and patients set treatment goals together, key factors affecting QoL should be considered.
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QoL

:   Quality of life
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